Center Laboratories (ROCO:4123) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4123 Center Laboratories Inc ROCO:4123
69 GF Score
Price NT$37.50
GF Value NT$43.04
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Center Laboratories Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Center Laboratories's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

ROCO:4123 vs ZTS, UTHR: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Center Laboratories Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Center Laboratories's Margin of Safety % (DCF Dividends Based) falls into.


ROCO:4123
69GF Score
Center Laboratories Inc ROCO:4123
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Center Laboratories (ROCO:4123) Overvalued in 2026?

Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued. The current stock price of NT$37.50 is trading 12.9% below its estimated GF Value™ of NT$43.04. GuruFocus considers Center Laboratories to be Modestly Undervalued.

Key valuation signals for ROCO:4123:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: NT$43.04 vs. price of NT$37.50 (12.9% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Center Laboratories Business Description

Address No. 3-2, Park Street, 7th floor, Nangang District, Taipei City, TWN, 115
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
69GF Score

Get the complete analysis for ROCO:4123

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$37.50
Price
NT$43.04
GF Value